Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A malignant mesenchymal fibroblastic neoplasm affecting the soft tissue and bone.
Biomarker and diagnostic research for fibrosarcoma has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
23 clinical trials registered, 12 recruiting. Interventions under study include drug therapy, procedural interventions, other interventions, and biologic therapy. Pipeline includes 1 PHASE3, 12 PHASE2, 6 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06239272](https://clinicaltrials.gov/study/NCT06239272) |
Data assembled from 4 of 12 sources · Last updated Sep 18, 2026, 5:27 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) |
PHASE1 |
St. Jude Children's Research Hospital |
RECRUITING |
[NCT07089992](https://clinicaltrials.gov/study/NCT07089992) | A Study of Pembrolizumab in People With Ultra-Rare Sarcomas | PHASE2 | Memorial Sloan Kettering Cancer Center | RECRUITING |
[NCT06277154](https://clinicaltrials.gov/study/NCT06277154) | MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma | PHASE2 | HRYZ Biotech Co. | RECRUITING |
[NCT06849986](https://clinicaltrials.gov/study/NCT06849986) | IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS) | PHASE2 | Fudan University | RECRUITING |
[NCT03967834](https://clinicaltrials.gov/study/NCT03967834) | Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group | NA | Institut Claudius Regaud | RECRUITING |
435 publications have been identified in PubMed for fibrosarcoma. Kisho has analyzed 213 by research type. Research spans Basic Science / Preclinical (40%), Case Report / Case Series (20%), and Review / Meta-Analysis (18%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 85 | 40% |
Patient case studies | 43 | 20% |
Research summaries | 39 | 18% |
New treatment approaches | 14 | 7% |
Testing and diagnosis research | 11 | 5% |
Clinical study results | 8 | 4% |
Disease patterns and progression | 8 | 4% |
Other research | 5 | 2% |
Pilkington T (2026). [PMID: 41369044](https://pubmed.ncbi.nlm.nih.gov/41369044/). *Am J Surg Pathol*. [Case Report / Case Series]
Pan H (2026). [PMID: 41779791](https://pubmed.ncbi.nlm.nih.gov/41779791/). *Proc Natl Acad Sci U S A*. [Basic Science / Preclinical]
Seuthe K (2026). [PMID: 42062840](https://pubmed.ncbi.nlm.nih.gov/42062840/). *Br J Pharmacol*. [Review / Meta-Analysis]
Liu M (2026). [PMID: 41771037](https://pubmed.ncbi.nlm.nih.gov/41771037/). *Clin Nucl Med*. [Diagnostic / Biomarker]
Arabi L (2026). [PMID: 41641141](https://pubmed.ncbi.nlm.nih.gov/41641141/). *Iran J Basic Med Sci*. [Other]
Petrenko V (2026). [PMID: 42068040](https://pubmed.ncbi.nlm.nih.gov/42068040/). *Biol Cell*. [Basic Science / Preclinical]
Saitoh Y (2026). [PMID: 41587625](https://pubmed.ncbi.nlm.nih.gov/41587625/). *Biochim Biophys Acta Gen Subj*. [Basic Science / Preclinical]
Miyashi Y (2026). [PMID: 41617463](https://pubmed.ncbi.nlm.nih.gov/41617463/). *Anticancer Res*. [Basic Science / Preclinical]
Crawford MJ (2026). [PMID: 41562145](https://pubmed.ncbi.nlm.nih.gov/41562145/). *Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc*. [Basic Science / Preclinical]
Miyashi Y (2026). [PMID: 41469126](https://pubmed.ncbi.nlm.nih.gov/41469126/). *Anticancer Res*. [Basic Science / Preclinical]